ANTIGENIC COMPOSITION AND SEROLOGIC CHARACTERISTICS OF DOMESTIC ACELLULAR PERTUSSIS VACCINE


Cite item

Full Text

Abstract

Aim. To assess antigenic composition consistency and serological characteristics of domestic acellular pertussis vaccine. Materials and methods. Amount of pertussis toxin, filamentous hemagglutinin, agglutinogens types 1, 2, and 3 in experimental batches of vaccine was measured by enzyme immunoassay. Levels of antibodies to aforementioned antigens as well as to lipopolysaccharide in serum samples obtained from patients with pertussis and healthy vaccinated children were measured by the same method. The amount of lypopolysaccharide was determined by LAL test. Results. Studied batches of vaccine were standard on amount of all protein antigens as well as lipopolysaccharide. Spectrum of antibodies to vaccine components in serum samples from patients with pertussis and healthy vaccinated children included antibodies to individual antigens: pertussis toxin, filamentous hemagglutinin, lipopolysaccharide, agglutinogens types 1, 2, and 3. Conclusion. Developed technology for manufacturing acellular pertussis vaccine allows to consistently produce preparations with standard amount of all components. Vaccine components interact with antibodies to wide spectrum of B.pertussis antigens.

Full Text

АНТИГЕННЫЙ СОСТАВ И СЕРОЛОГИЧЕСКИЕ СВОЙСТВА ОТЕЧЕСТВЕННОЙ БЕСКЛЕТОЧНОЙ КОКЛЮШНОЙ ВАКЦИНЫ
×

About the authors

E. M Zaitsev

Mechnikov Research Institute of Vaccines and Sera; Gabrichevsky Research Institute of Epidemiology and Microbiology; Infectious Diseases Clinical Hospital No. 1, Moscow, Russia

A. V Poddubikov

Mechnikov Research Institute of Vaccines and Sera; Gabrichevsky Research Institute of Epidemiology and Microbiology; Infectious Diseases Clinical Hospital No. 1, Moscow, Russia

M. V Britsina

Mechnikov Research Institute of Vaccines and Sera; Gabrichevsky Research Institute of Epidemiology and Microbiology; Infectious Diseases Clinical Hospital No. 1, Moscow, Russia

N. U Mertsalova

Mechnikov Research Institute of Vaccines and Sera; Gabrichevsky Research Institute of Epidemiology and Microbiology; Infectious Diseases Clinical Hospital No. 1, Moscow, Russia

I. G Bazhanova

Mechnikov Research Institute of Vaccines and Sera; Gabrichevsky Research Institute of Epidemiology and Microbiology; Infectious Diseases Clinical Hospital No. 1, Moscow, Russia

M. N Ozeretskovskaya

Mechnikov Research Institute of Vaccines and Sera; Gabrichevsky Research Institute of Epidemiology and Microbiology; Infectious Diseases Clinical Hospital No. 1, Moscow, Russia

M. R Nazirov

Mechnikov Research Institute of Vaccines and Sera; Gabrichevsky Research Institute of Epidemiology and Microbiology; Infectious Diseases Clinical Hospital No. 1, Moscow, Russia

I. K Mazurova

Mechnikov Research Institute of Vaccines and Sera; Gabrichevsky Research Institute of Epidemiology and Microbiology; Infectious Diseases Clinical Hospital No. 1, Moscow, Russia

M. S Petrova

Mechnikov Research Institute of Vaccines and Sera; Gabrichevsky Research Institute of Epidemiology and Microbiology; Infectious Diseases Clinical Hospital No. 1, Moscow, Russia

O. P Popova

Mechnikov Research Institute of Vaccines and Sera; Gabrichevsky Research Institute of Epidemiology and Microbiology; Infectious Diseases Clinical Hospital No. 1, Moscow, Russia

N. S Zakharova

Mechnikov Research Institute of Vaccines and Sera; Gabrichevsky Research Institute of Epidemiology and Microbiology; Infectious Diseases Clinical Hospital No. 1, Moscow, Russia

References

  1. Бабаченко И.В., Курова Н.Н., Ценева Г.Я. Коклюшная инфекция в условиях антигенного дрейфа Bordetella pertussis. Вопр. совр. педиатр. 2006, 5 (6): 25-27.
  2. Зайцев Е.М., Мазурова И.К., Петрова М.С. и др. Диагностическое значение IgG, IgA и IgM к антигенам Bordetella pertussis у больных коклюшем. Журн. микробиол. 2008, 6: 23-26.
  3. Захарова Н.С., Брицина М.В., Мерцалова Н.У. и др. Отечественная бесклеточная вакцина. Там же. 2008, 1: 35-41.
  4. Таточенко В.К., Озерецковский Н.А., Федоров А.М. Иммунопрофилактика–2009. М., ИПК Континент-Пресс, 2009.
  5. Чистякова Г.Г., Борисова О.Ю., Лыткина И.Н. и др. Особенности эпидемического процесса коклюшной инфекции в Москве. Журн. микробиол. 2005, 5: 35-40.
  6. Chodorowska M. Humoral reaction to Bordetella pertussis antigens: pertussis toxin, filamentous hemagglutinin and lipopolysaccharide in children with clinical symptoms of whooping cough. II. Occurrence and level of B. pertussis antigens in children with suspected whooping cough. Med. Dosw. Microbiol. 1999, 51 (3—4): 269-280.
  7. Geurtsen J., Banus H.A., Gremmer E.R. et al. Lipooligosaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. Clin. Vac. Immunol. 2007, 14 (7): 821-829.
  8. Fedele G., Celestino I., Spensieri F. et al. Lipooligosaccharide from Bordetella pertussis induces mature human monocyte — derived dendritic cells and drives a Th2 biased response. Microb. Infect. 2007, 9 (7): 855-863.
  9. He O., Mertsola J. Factors contributing to pertus- sis resurgence. Fut. Microbiol. 2008, 3: 329-339.
  10. Poolman J.T., Hallander H.O. Acellular pertussis vaccines and the role of pertactin and fimbria. Expert. Rev. Vac. 2007, 6 (1): 47-56.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Zaitsev E.M., Poddubikov A.V., Britsina M.V., Mertsalova N.U., Bazhanova I.G., Ozeretskovskaya M.N., Nazirov M.R., Mazurova I.K., Petrova M.S., Popova O.P., Zakharova N.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies